CoronaVac vaccine is effective in preventing symptomatic and severe COVID‑19 in pregnant women in Brazil: a test‑negative case‑control study

dc.creatorPaixao, Enny S.
dc.creatorWong, Kerry L. M.
dc.creatorAlves, Flavia Jôse Oliveira
dc.creatorOliveira, Vinicius de Araújo
dc.creatorSilva, Thiago Cerqueira
dc.creatorBertoldo Júnior, Juracy
dc.creatorMachado, Tales Mota
dc.creatorPinto Junior, Elzo Pereira
dc.creatorBoaventura, Viviane S.
dc.creatorPenna, Gerson O.
dc.creatorWerneck, Guilherme Loureiro
dc.creatorRodrigues, Laura C.
dc.creatorPearce, Neil
dc.creatorBarreto, Mauricio L.
dc.creatorBarral Netto, Manoel
dc.date2022-05-09T19:21:09Z
dc.date2022-05-09T19:21:09Z
dc.date2022
dc.date.accessioned2023-09-26T22:43:33Z
dc.date.available2023-09-26T22:43:33Z
dc.identifierPAIXÃO, Enny S. et al. CoronaVac vaccine is effective in preventing symptomatic and severe COVID‑19 in pregnant women in Brazil: a test‑negative case‑control study. BMC Medicine, v. 20, n. 146, p. 1-8, 2022.
dc.identifier1741-7015
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/52591
dc.identifier10.1186/s12916-022-02353-w
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8882422
dc.descriptionPrograma VigiVac Fiocruz. Programa “Fazer o bem faz bem”. Wellcome Trust.
dc.descriptionBackground: More doses of CoronaVac have been administered worldwide than any other COVID-19 vaccine. However, the effectiveness of COVID-19 inactivated vaccines in pregnant women is still unknown. We estimated the vaccine effectiveness (VE) of CoronaVac against symptomatic and severe COVID-19 in pregnant women in Brazil. Methods: We conducted a test-negative design study in all pregnant women aged 18–49 years with COVID-19-related symptoms in Brazil from March 15, 2021, to October 03, 2021, linking records of negative and positive SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) tests to national vaccination records. We also linked records of test-positive cases with notifications of severe, hospitalised or fatal COVID-19. Using logistic regression, we estimated the adjusted odds ratio and VE against symptomatic COVID-19 and against severe COVID-19 by comparing vaccine status in test-negative subjects to test-positive symptomatic cases and severe cases. Results: Of the 19,838 tested pregnant women, 7424 (37.4%) tested positive for COVID-19 and 588 (7.9%) had severe disease. Only 83% of pregnant women who received the first dose of CoronaVac completed the vaccination scheme. A single dose of the CoronaVac vaccine was not effective at preventing symptomatic COVID-19. The effectiveness of two doses of CoronaVac was 41% (95% CI 27.1–52.2) against symptomatic COVID-19 and 85% (95% CI 59.5–94.8) against severe COVID-19. Conclusions: A complete regimen of CoronaVac in pregnant women was effective in preventing symptomatic COVID-19 and highly effective against severe illness in a setting that combined high disease burden and marked COVID-19-related maternal deaths.
dc.formatapplication/pdf
dc.languageeng
dc.publisherBMC
dc.rightsopen access
dc.subjectVaccines
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectEficácia da vacina
dc.subjectVacina inativada
dc.subjectMulheres grávidas
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectVaccine effectiveness
dc.subjectInactivated vaccine
dc.subjectPregnant women
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectEficacia de la vacuna
dc.subjectVacuna inactivada
dc.subjectMujeres embarazadas
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectEfficacité du vaccin
dc.subjectVaccin inactivé
dc.subjectFemmes enceintes
dc.subjectCOVID-19
dc.subjectSRAS-CoV-2
dc.subjectVacinas
dc.subjectVacinas de Produtos Inativados
dc.subjectGestantes
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.titleCoronaVac vaccine is effective in preventing symptomatic and severe COVID‑19 in pregnant women in Brazil: a test‑negative case‑control study
dc.typeArticle


Este ítem pertenece a la siguiente institución